Pfizer’s (NYSE:PFE) 25 percent profit growth with $15 billion in revenue came as a surprise to some expecting the company to still be hurting from the loss of its patent for blockbuster drug Lipitor last year. Its streamlined approach to its research and development division implemented last year including a shift in the way it […]
The U.S. Food and Drug Administration has approved the expanded use of Pfizer’s (NYSE:PFE) blockbuster pain medication Lyrica for neuropathic pain associated with spinal injury, according to a company statement. It received the approval to treat the chronic pain condition under the FDA’s priority review designation for the new indication. There are an estimated 270,000 […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Clinical research organization PPD has hired a Pfizer (NYSE:PFE) veteran to become its new CEO. David Simmons brings 15 years experience at the world’s largest pharmaceutical company to PPD, which is one of the largest CROs in the pharmaceutical services industry. The CEO post became vacant after PPD was taken private in a $3.9 billion […]
Antares Pharma (AMEX:AIS) has inked a licensing agreement with Pfizer (NYSE:PFE) to provide one of its drug-delivery technologies to Pfizer’s consumer healthcare business arm for an unnamed product for North America. Pfizer, in New York, will be responsible for clinical development, manufacturing and commercialization of the product. Ewing, New Jersey-based Antares will receive up-front payments, […]
Nearly one-third of Icagen (NASDAQ:ICGN) shareholders have yet to accept Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company and the pharmaceutical giant is giving them one last chance. The expiration date for the offer at $6 per share in cash has been extended one week. But Pfizer, which extended its tender offer […]
Pfizer‘s (NYSE:PFE) Icagen (NASDAQ:ICGN) acquisition is a go. After two extensions last week, Pfizer announced today that it has enough shares tendered for sale for the $56 million cash deal to proceed at the price of $6 per share. As of the 6 p.m. deadline on Sept. 2, 64 percent of outstanding shares of Icagen, […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Icagen‘s (NASDAQ:ICGN) sale to Pfizer (NYSE:PFE) hangs in the balance by 39,799 shares. That’s the minimum number of shares that need to be tendered for the $56 million sale to proceed. Pfizer extended to 6 p.m. today the expiration date of its offer. In July, Pfizer announced an agreement with Icagen to acquire the pain […]
Pfizer‘s (NYSE:PFE) $56 million offer for Icagen (NASDAQ:ICGN) has been extended one more day as the pharmaceutical giant remains just shy of the minimum shares needed to execute the acquisition. Unless there is another extension, Pfizer’s Icagen offer now expires midnight tonight. As of midnight Aug. 31, the 49 percent of diluted shares tendered was […]
Pfizer (NYSE:PFE) will not raise its offer to acquire Icagen (NASDAQ:ICGN). The pharmaceutical giant sent a letter to Icagen’s board of directors today holding firm on its purchase price of $6 per share, which amounts to $56 million. Douglas Giordano, senior vice president, worldwide business development, wrote that with the approaching Aug. 31 expiration of […]
Pharmaceutical companies on Facebook for years have had a decidedly one-way relationship on the social networking site: Pharmas could post about their drugs, but the public could not write on pharma’s walls. Now that’s changed. Facebook will no longer allow pharmaceutical companies to block comments, a healthcare social media policy change that has led some […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Two Icagen (NASDAQ:ICGN) institutional investors opposed to Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company now say the company’s value should be nearly three times that amount. Merlin Nexus and New Leaf Venture Partners say that with potential sales of pain treatment products exceeding $2 billion a year, they value Durahm, North […]
Pfizer‘s (NYSE:PFE) $56 million offer to acquire Icagen (NASDAQ:ICGN) followed a mostly fruitless courtship dating back five years that ultimately saw the pharma giant beat out two others who vied for all or part of the pain drug company. Pfizer’s offer, which amounts to $6 per share, is now under challenge by some shareholders as […]
GlaxoSmithKline (NYSE:GSK) is moving to protect its top-selling HIV drug Epzicom from generic drug competition. ViiV Healthcare, the HIV joint venture of GSK and Pfizer (NYSE:PFE), is suing Teva Pharmaceutical (NASDAQ:TEVA) for infringing on HIV drug Epzicom in violation of the drug’s patent, Bloomberg News reports. The Aug. 5 complaint was filed in federal court […]
Pfizer’s (NYSE:PFE) $56 million bid to acquire Icagen (NASDAQ:ICGN) faces a big hurdle — two of Icagen’s largest shareholders. Merlin Nexus and New Leaf Venture Partners, two firms holding Icagen stock, submitted a July 28 letter to the Icagen board contesting the deal, saying they “believe the purchase price dramatically undervalues Icagen’s assets and is […]
Pfizer (NYSE:PFE) is now talking about a possible acquisition of Icagen (NASDAQ:ICGN). But, already, Pfizer is Icagen’s primary supporter. Icagen, which is based in Durham, North Carolina, has relied on a 2007 partnership with Pfizer to develop drug candidates to treat pain. Icagen’s compounds modulate ion channels, which are protein structures found in the cells […]